BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 20506062)

  • 41. Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.
    Quintás-Cardama A; Verstovsek S
    Clin Cancer Res; 2013 Apr; 19(8):1933-40. PubMed ID: 23406773
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib.
    Wilkins BS; Radia D; Woodley C; Farhi SE; Keohane C; Harrison CN
    Haematologica; 2013 Dec; 98(12):1872-6. PubMed ID: 24056820
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An updated review of the JAK1/2 inhibitor (ruxolitinib) in the Philadelphia-negative myeloproliferative neoplasms.
    Curto-Garcia N; Harrison CN
    Future Oncol; 2018 Jan; 14(2):137-150. PubMed ID: 29056075
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms.
    Greenfield G; McPherson S; Mills K; McMullin MF
    J Transl Med; 2018 Dec; 16(1):360. PubMed ID: 30558676
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ruxolitinib: A Review in Polycythaemia Vera.
    McKeage K
    Drugs; 2015 Oct; 75(15):1773-81. PubMed ID: 26362333
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.
    Liu PC; Caulder E; Li J; Waeltz P; Margulis A; Wynn R; Becker-Pasha M; Li Y; Crowgey E; Hollis G; Haley P; Sparks RB; Combs AP; Rodgers JD; Burn TC; Vaddi K; Fridman JS
    Clin Cancer Res; 2009 Nov; 15(22):6891-900. PubMed ID: 19887489
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post--polycythemia vera/essential thrombocythemia myelofibrosis (post--PV/ET MF).
    Mascarenhas J; Marcellino BK; Lu M; Kremyanskaya M; Fabris F; Sandy L; Mehrotra M; Houldsworth J; Najfeld V; El Jamal S; Petersen B; Moshier E; Hoffman R
    Leuk Res; 2020 Jan; 88():106272. PubMed ID: 31778911
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management.
    Bose P; Verstovsek S
    J Natl Compr Canc Netw; 2016 Dec; 14(12):1613-1624. PubMed ID: 27956543
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.
    Bartalucci N; Guglielmelli P; Vannucchi AM
    Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S307-9. PubMed ID: 24290217
    [TBL] [Abstract][Full Text] [Related]  

  • 50. JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis.
    Hsu L; Armstrong AW
    J Immunol Res; 2014; 2014():283617. PubMed ID: 24883332
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Not Available].
    Soret J; Kiladjian JJ
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S29-38. PubMed ID: 27494970
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?
    Pardanani A; Tefferi A
    Leuk Lymphoma; 2014 Dec; 55(12):2706-11. PubMed ID: 25520049
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tumor Lysis Syndrome after the Administration of Ruxolitinib in a Patient with Post-polycythemia Vera Myelofibrosis.
    Koshiishi M; Sueki Y; Kawashima I; Nakajima K; Mitsumori T; Kirito K
    Intern Med; 2017 Sep; 56(17):2335-2338. PubMed ID: 28794380
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.
    Bhagwat N; Levine RL; Koppikar P
    Int J Hematol; 2013 Jun; 97(6):695-702. PubMed ID: 23670175
    [TBL] [Abstract][Full Text] [Related]  

  • 55. What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?
    Vannucchi AM; Guglielmelli P
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):480-488. PubMed ID: 29222296
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib.
    Mascarenhas J; Mughal TI; Verstovsek S
    Curr Med Chem; 2012; 19(26):4399-413. PubMed ID: 22830345
    [TBL] [Abstract][Full Text] [Related]  

  • 57. JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms.
    O'Sullivan JM; Harrison CN
    Mol Cell Endocrinol; 2017 Aug; 451():71-79. PubMed ID: 28167129
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study.
    Naqvi K; Daver N; Pemmaraju N; Bose P; Garcia-Manero G; Cortes J; Kantarjian HM; Verstovsek S
    Leuk Lymphoma; 2017 Apr; 58(4):866-871. PubMed ID: 27494751
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Ruxolitinib prescription in myelofibrosis].
    Lemal R; Robin M; Ravinet A; Cacheux V; Guièze R; Bay JO
    Bull Cancer; 2013 Sep; 100(9):897-902. PubMed ID: 23985569
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia.
    Pemmaraju N; Kantarjian H; Kadia T; Cortes J; Borthakur G; Newberry K; Garcia-Manero G; Ravandi F; Jabbour E; Dellasala S; Pierce S; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):171-6. PubMed ID: 25441108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.